Clinical Trial Update: A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects [Phase 1]

View source ↗

Summary

A Phase I study of a single subcutaneous dose of HRS-5632 in healthy subjects was completed to assess safety, tolerability, and pharmacokinetics for potential d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• HRS-5632

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Dyslipidemia | Phase 1 | Status: COMPLETED